A new chapter in TAVI evidence is taking shape. PARADIGM Trial is the first head-to-head TAVI trial using cardiac MRI to evaluate post-TAVI flow, offering new insight into valve performance and LV mass regression. The randomized head-to-head trial is evaluating the DurAVR® THV System compared to commercially available Transcatheter Aortic Valve Replacement (TAVR) devices in patients with severe aortic stenosis. In part one, Prof Ole De Backer and Prof Nicolas van Mieghem discuss the PARADIGM Tri